Disc Medicine, Inc. (NASDAQ:IRON) is Bain Capital Life Sciences Investors LLC's 4th Largest Position

Bain Capital Life Sciences Investors LLC reduced its position in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 45.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 983,500 shares of the company's stock after selling 812,235 shares during the quarter. Disc Medicine comprises about 7.3% of Bain Capital Life Sciences Investors LLC's portfolio, making the stock its 4th biggest position. Bain Capital Life Sciences Investors LLC owned 3.30% of Disc Medicine worth $62,354,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of IRON. Sterling Capital Management LLC raised its position in shares of Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock valued at $36,000 after purchasing an additional 503 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Disc Medicine by 47.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock valued at $52,000 after acquiring an additional 266 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Disc Medicine in the 4th quarter valued at $235,000. Teacher Retirement System of Texas boosted its stake in shares of Disc Medicine by 8.9% during the 4th quarter. Teacher Retirement System of Texas now owns 4,857 shares of the company's stock worth $308,000 after acquiring an additional 396 shares in the last quarter. Finally, Virtu Financial LLC purchased a new stake in shares of Disc Medicine in the fourth quarter valued at approximately $309,000. 83.70% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO John D. Quisel sold 5,574 shares of the company's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total transaction of $304,228.92. Following the sale, the chief executive officer now directly owns 154,828 shares in the company, valued at approximately $8,450,512.24. This represents a 3.48 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Rahul Khara sold 7,500 shares of Disc Medicine stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $55.54, for a total transaction of $416,550.00. Following the completion of the transaction, the insider now owns 14,035 shares of the company's stock, valued at $779,503.90. This represents a 34.83 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 361,690 shares of company stock valued at $19,648,094 in the last ninety days. Company insiders own 4.24% of the company's stock.

Analysts Set New Price Targets

IRON has been the topic of several research analyst reports. Morgan Stanley reiterated an "overweight" rating and issued a $85.00 target price on shares of Disc Medicine in a research report on Friday, March 7th. TD Cowen initiated coverage on Disc Medicine in a research note on Thursday, February 27th. They set a "buy" rating for the company. Stifel Nicolaus raised their target price on Disc Medicine from $90.00 to $94.00 and gave the company a "buy" rating in a research report on Friday, January 24th. Cantor Fitzgerald boosted their price target on Disc Medicine from $99.00 to $132.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 18th. Finally, Scotiabank increased their price objective on Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a research note on Monday, March 3rd. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Disc Medicine has an average rating of "Buy" and an average price target of $93.80.

Disc Medicine Trading Down 1.6 %

IRON stock traded down $0.75 during trading on Friday, reaching $45.42. 273,679 shares of the stock were exchanged, compared to its average volume of 345,399. The firm has a market capitalization of $1.57 billion, a price-to-earnings ratio of -11.41 and a beta of 0.77. The business has a 50 day moving average price of $48.73 and a 200-day moving average price of $55.04. Disc Medicine, Inc. has a 1 year low of $25.64 and a 1 year high of $68.73.

Disc Medicine (NASDAQ:IRON - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.06) by $0.08. On average, research analysts anticipate that Disc Medicine, Inc. will post -4.07 EPS for the current year.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.